RE:RE:RE:RE:RE:Volume 131,400 in Canada
Again today RBC is the seller, on the other side Anonymus (that's me in this case) is the buyer. This is certainly about year-end prices.
The positive future possibilities have been mentioned here several times by Proph and Lauren.
On the other hand, it has to be seen that the overall market might remain negative and Ceapro could show lower profits due to higher costs for research and investments.
If Avenanthramide goes wrong (which I don't think it will) and profits fall at the same time, further share price declines are likely.
Another quick comment for HOPE because you always whine about sales volume. As I myself was a trader on the stock exchange and have bought Ceapro for clients from time to time in recent months, I can tell you that it is quite common on the stock exchange to apply purchases and sales of a brokerage house, i.e. 100,000 shares can be traded without them even being displayed.